Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) Stock Information | RedChip

Enanta Pharmaceuticals Inc. (NASDAQ: ENTA)


$6.1300
-0.2400 ( +0.82% ) 221.9K

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Market Data


Open


$6.1300

Previous close


$6.3700

Volume


221.9K

Market cap


$126.11M

Day range


$5.7300 - $6.2250

52 week range


$5.7000 - $17.8000

SEC Filings


Form Type Description Pages Date
8-k 8K-related 13 Nov 25, 2024
4 Insider transactions 2 Aug 09, 2024
10-q Quarterly Reports 65 Aug 07, 2024
8-k 8K-related 13 Aug 05, 2024
4 Insider transactions 1 Jul 15, 2024
4 Insider transactions 1 Jun 17, 2024
10-q Quarterly Reports 63 May 08, 2024
8-k 8K-related 13 May 06, 2024
3 Insider transactions 2 May 01, 2024
4 Insider transactions 1 May 01, 2024

Latest News